PMC:7228307 / 2443-2736
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T13 | 4-12 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T31 | 274-275 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 28-40 | Sentence | denotes | Introduction |
T18 | 41-176 | Sentence | denotes | The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T13 | 4-12 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 28-40 | Sentence | denotes | Introduction |
T18 | 41-176 | Sentence | denotes | The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. |